title: Comparative efficacy of tigecycline VERSUS vancomycin in an experimental model of soft tissue infection by methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin.
abstract: Methicillin-resistant Staphylococcus aureus (MRSA) producing Panton-Valentine leukocidin (PVL) is highly virulent. This study aimed to compare the efficacy of tigecycline versus vancomycin in experimental thigh abscess by a PVL-producing MRSA isolate. One hundred and ninety-six Wistar rats were divided into five groups: group A, controls; groups B and C, administered vancomycin starting 1 and 6 h after bacterial challenge respectively; groups D and E, administered tigecycline starting 1 and 6 h after bacterial challenge respectively. Treatment was continued every 12 hours for three consecutive days. Survival was recorded; separate animals were killed for quantitative cultures. Serum samples were collected for estimation of malondialdehyde (MDA). Survival of group D was prolonged compared to all other groups. The bacterial load of blood, liver, spleen and lung was significantly decreased within group D compared to group B at 36 hours. Treatment with tigecycline was accompanied by significant reduction of serum MDA at 24 hours. Tigecycline is comparable to vancomycin for the treatment of soft tissue infections by PVL-producing MRSA.
authors.forename: Anastasia
authors.initials: A
authors.lastname: Antonopoulou
authors.forename: Thomas
authors.initials: T
authors.lastname: Tsaganos
authors.forename: Ira-Maria
authors.initials: IM
authors.lastname: Tzepi
authors.forename: Helen
authors.initials: H
authors.lastname: Giamarellou
authors.forename: Evangelos J
authors.initials: EJ
authors.lastname: Giamarellos-Bourboulis
mesh_terms: D000038:Abscess / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D058491:Bacterial Load / Q000187:drug effects; D001427:Bacterial Toxins / Q000096:biosynthesis*; D004334:Drug Administration Schedule; D005098:Exotoxins / Q000096:biosynthesis*; D016867:Immunocompromised Host / Q000187:drug effects / Q000276:immunology; D007274:Injections, Intraperitoneal; D053208:Kaplan-Meier Estimate; D007956:Leukocidins / Q000096:biosynthesis*; D015227:Lipid Peroxidation; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification / Q000378:metabolism / Q000472:pathogenicity; D008911:Minocycline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011897:Random Allocation; D017208:Rats, Wistar; D018461:Soft Tissue Infections / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000382:microbiology; D013848:Thigh; D000078304:Tigecycline; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D014774:Virulence / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D001427:Bacterial Toxins; D005098:Exotoxins; D007956:Leukocidins; C078284:Panton-Valentine leukocidin; D014640:Vancomycin; D000078304:Tigecycline; D008911:Minocycline
keywords: MRSA,; Panton-valentine leukocidin,; Tigecycline,; Vancomycin